Literature DB >> 33671378

Immunogenicity of Calvenza-03 EIV/EHV® Vaccine in Horses: Comparative In Vivo Study.

Selvaraj Pavulraj1, Tobias Bergmann1, Claudia Maria Trombetta2, Serena Marchi2, Emanuele Montomoli2,3, Sidi Sefiane El Alami4, Roberto Ragni-Alunni5, Nikolaus Osterrieder1,6, Walid Azab1.   

Abstract

Equine influenza (EI) is a highly contagious acute respiratory disease of equines that is caused mainly by the H3N8 subtype of influenza A virus. Vaccinating horses against EI is the most effective strategy to prevent the infection. The current study aimed to compare the kinetics of EI-specific humoral- and cell-mediated immunity (CMI) in horses receiving either identical or mixed vaccinations. Two groups of horses were previously (six months prior) vaccinated with either Calvenza 03 EIV EHV® (G1) or Fluvac Innovator® (G2) vaccine. Subsequently, both groups received a booster single dose of Calvenza 03 EIV EHV®. Immune responses were assessed after 10 weeks using single radial hemolysis (SRH), virus neutralization (VN), and EliSpot assays. Our results revealed that Calvenza-03 EIV/EHV®-immunized horses had significantly higher protective EI-specific SRH antibodies and VN antibodies. Booster immunization with Calvenza-03 EIV/EHV® vaccine significantly stimulated cell-mediated immune response as evidenced by significant increase in interferon-γ-secreting peripheral blood mononuclear cells. In conclusion, Calvenza-03 EIV/EHV® vaccine can be safely and effectively used for booster immunization to elicit optimal long persisting humoral and CMI responses even if the horses were previously immunized with a heterogeneous vaccine.

Entities:  

Keywords:  Florida clade 2; equine influenza; horses; immunogenicity; vaccination

Year:  2021        PMID: 33671378     DOI: 10.3390/vaccines9020166

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  2 in total

Review 1.  Equine Influenza Virus and Vaccines.

Authors:  Fatai S Oladunni; Saheed Oluwasina Oseni; Luis Martinez-Sobrido; Thomas M Chambers
Journal:  Viruses       Date:  2021-08-20       Impact factor: 5.818

2.  Evaluation of concurrent vaccinations with recombinant canarypox equine influenza virus and inactivated equine herpesvirus vaccines.

Authors:  Dong-Ha Lee; Eun-Bee Lee; Jong-Pil Seo; Eun-Ju Ko
Journal:  J Anim Sci Technol       Date:  2022-05-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.